Abstract
Respiratory diseases including chronic-obstructive-pulmonary-disease (COPD) are globally increasing, with COPD predicted to become the third leading cause of global mortality by 2020. COPD is a heterogeneous disease with COPD-patients displaying different phenotypes as a result of a complex interaction between various genetic, environmental and life-style factors. In recent years, several investigations have been performed to better define such interactions, but the identification of the resulting phenotypes is still somewhat difficult, and may lead to inadequate assessment and management of COPD (usually based solely on the severity of airflow limitation parameter FEV1). In this new scenario, the management of COPD has been driven towards an integrative and holistic approach. The degree of complexity requires analyses based on large datasets (also including advanced functional genomic assays) and novel computational biology approaches (essential to extract information relevant for the clinical decision process and for the development of new drugs). Therefore, according to the emerging “systems/network medicine”, COPD should be re.-evaluated considering multiple network(s) perturbations such as genetic and environmental changes. Systems Medicine (SM) platforms, in which patients are extensively characterized, offer a basis for a more targeted clinical approach, which is predictive, preventive, personalized and participatory (“P4-medicine”). It clearly emerges that in the next future, new opportunities will become available for clinical research on rare COPD patterns and for the identification of new biomarkers of comorbidity, severity, and progression. Herein, we overview the literature discussing the opportunity coming from the adoption of SMapproaches in COPD management, focusing on proteomics and metabolomics, and emphasizing the identification of disease sub-clusters, to improve the development of more effective therapies.
Keywords: COPD, Comorbidities, Metabolomics, Systems Medicine, Proteomics, P4 Medicine.
Current Medicinal Chemistry
Title:Novel Therapeutic Strategy in the Management of COPD: A Systems Medicine Approach
Volume: 22 Issue: 32
Author(s): Filippo Lococo, Alfredo Cesario, Alessandra Del Bufalo, Alessia Ciarrocchi, Giulia Prinzi, Marco Mina, Stefano Bonassi and Patrizia Russo
Affiliation:
Keywords: COPD, Comorbidities, Metabolomics, Systems Medicine, Proteomics, P4 Medicine.
Abstract: Respiratory diseases including chronic-obstructive-pulmonary-disease (COPD) are globally increasing, with COPD predicted to become the third leading cause of global mortality by 2020. COPD is a heterogeneous disease with COPD-patients displaying different phenotypes as a result of a complex interaction between various genetic, environmental and life-style factors. In recent years, several investigations have been performed to better define such interactions, but the identification of the resulting phenotypes is still somewhat difficult, and may lead to inadequate assessment and management of COPD (usually based solely on the severity of airflow limitation parameter FEV1). In this new scenario, the management of COPD has been driven towards an integrative and holistic approach. The degree of complexity requires analyses based on large datasets (also including advanced functional genomic assays) and novel computational biology approaches (essential to extract information relevant for the clinical decision process and for the development of new drugs). Therefore, according to the emerging “systems/network medicine”, COPD should be re.-evaluated considering multiple network(s) perturbations such as genetic and environmental changes. Systems Medicine (SM) platforms, in which patients are extensively characterized, offer a basis for a more targeted clinical approach, which is predictive, preventive, personalized and participatory (“P4-medicine”). It clearly emerges that in the next future, new opportunities will become available for clinical research on rare COPD patterns and for the identification of new biomarkers of comorbidity, severity, and progression. Herein, we overview the literature discussing the opportunity coming from the adoption of SMapproaches in COPD management, focusing on proteomics and metabolomics, and emphasizing the identification of disease sub-clusters, to improve the development of more effective therapies.
Export Options
About this article
Cite this article as:
Lococo Filippo, Cesario Alfredo, Bufalo Del Alessandra, Ciarrocchi Alessia, Prinzi Giulia, Mina Marco, Bonassi Stefano and Russo Patrizia, Novel Therapeutic Strategy in the Management of COPD: A Systems Medicine Approach, Current Medicinal Chemistry 2015; 22 (32) . https://dx.doi.org/10.2174/0929867322666150904113032
DOI https://dx.doi.org/10.2174/0929867322666150904113032 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Novel Anti-Platelets in Stable Coronary Artery Disease
Current Pharmaceutical Design Dapsone, More than an Effective Neuro and Cytoprotective Drug
Current Neuropharmacology Carotid Intima Media Thickness and Beyond
Current Drug Targets - Cardiovascular & Hematological Disorders Embolic Protection Devices in Saphenous Vein Graft and Native Vessel Percutaneous Intervention: A Review
Current Cardiology Reviews Virulence Potential of Staphylococcus aureus Strains Isolated from Diabetic Foot Ulcers Among Patients from Southern Poland
Current Vascular Pharmacology Menopausal Transition and Chronic Diseases
Current Women`s Health Reviews Postprandial Hypotension - Novel Insights into Pathophysiology and Therapeutic Implications
Current Vascular Pharmacology Manipulating Thymic Apoptosis for Future Therapy of Autoimmune Diseases
Current Pharmaceutical Design Pharmacogenetics of HMG-CoA Reductase Inhibitors: Optimizing the Prevention of Coronary Heart Disease
Current Pharmacogenomics and Personalized Medicine High-sensitive Cardiospecific Troponins: The Role of Sex-specific Concentration in the Diagnosis of Acute Coronary Syndrome (Mini-Review)
Cardiovascular & Hematological Agents in Medicinal Chemistry Tobacco Smoking and Association between Betel Nut Chewing and Metabolic Abnormalities Among Military Males: The CHIEF Study
Endocrine, Metabolic & Immune Disorders - Drug Targets Role of Vitamins in Cardiovascular Health: Know Your Facts-Part 2
Current Vascular Pharmacology Nanotechnology and Antioxidant Therapy: An Emerging Approach for Neurodegenerative Diseases
Current Medicinal Chemistry New Assay for Old Markers-Plasma Beta Amyloid of Mild Cognitive Impairment and Alzheimer’s Disease
Current Alzheimer Research Impact of Traditional Therapies and Biologics on Cardiovascular Diseases in Rheumatoid Arthritis
Current Vascular Pharmacology From Na+/K+-ATPase and Cardiac Glycosides to Cytotoxicity and Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Serum Creatinine vs. Albuminuria as Biomarkers for the Estimation of Cardiovascular Risk
Current Vascular Pharmacology A Role for Endothelin-1 in Peripheral Vascular Disease
Current Vascular Pharmacology New Strategy on Antimicrobial-resistance: Inhibitors of DNA Replication Enzymes
Current Medicinal Chemistry HDL-C Levels and Cardiovascular Disease: More is not Always Better!
Recent Patents on Cardiovascular Drug Discovery